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Abstract 25 
The arsenal of drugs used to treat leishmaniasis, caused by Leishmania spp., is limited 26 
and beset by toxicity and emergent resistance. Furthermore, our understanding of drug 27 
mode-of-action and potential routes to resistance is limited. Forward genetic approaches 28 
have revolutionised our understanding of drug mode-of-action in the related kinetoplastid 29 
parasite, Trypanosoma brucei. Therefore, we screened our genome-scale T. brucei RNAi 30 
library in the current anti-leishmanial drugs, sodium stibogluconate (antimonial), 31 
paromomycin, miltefosine and amphotericin-B. Identification of T. brucei orthologues of the 32 
known Leishmania antimonial and miltefosine plasma membrane transporters effectively 33 
validated our approach, while a cohort of 42 novel drug efficacy determinants provides 34 
new insights and serves as a resource. Follow-up analyses revealed the antimonial 35 
selectivity of the aquaglyceroporin, TbAQP3. A lysosomal major facilitator superfamily 36 
transporter contributes to paromomycin/aminoglycoside efficacy. The vesicle-associated 37 
membrane protein, TbVAMP7B, and a flippase contribute to amphotericin-B and 38 
miltefosine action, and are potential cross-resistance determinants. Finally, multiple 39 
phospholipid-transporting flippases, including the T. brucei orthologue of the Leishmania 40 
miltefosine transporter, a putative β-subunit/CDC50 co-factor, and additional membrane-41 
associated hits, affect amphotericin-B efficacy, providing new insights into mechanisms of 42 
drug uptake and action. The findings from this orthology-based chemogenomic profiling 43 
approach substantially advance our understanding of anti-leishmanial drug action and 44 
potential resistance mechanisms, and should facilitate the development of improved 45 
therapies, as well as surveillance for drug-resistant parasites.  46 
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Importance 47 
Leishmaniasis is a devastating disease caused by the Leishmania parasites and is 48 
endemic to a wide swathe of the tropics and sub-tropics. While there are drugs available 49 
for the treatment of leishmaniasis, these suffer from various challenges, including the 50 
spread of drug resistance. Our understanding of anti-leishmanial drug action and the 51 
modes of drug resistance in Leishmania is limited. The development of genetic screening 52 
tools in the related parasite, Trypanosoma brucei, has revolutionised our understanding of 53 
these processes in this parasite. Therefore, we applied these tools to the anti-leishmanial 54 
drugs, identifying T. brucei orthologues of known Leishmania proteins that drive drug 55 
uptake, as well as a panel of novel proteins not previously associated with anti-leishmanial 56 
drug action. Our findings substantially advance our understanding of anti-leishmanial 57 
mode-of-action and provide a valuable starting point for further research.  58 
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Introduction 59 
 The kinetoplastid parasites, Leishmania species, Trypanosoma brucei subspecies 60 
and T. cruzi are respectively endemic throughout much of the tropics and sub-tropics, sub-61 
Saharan Africa and Latin America. They are responsible for various forms of leishmaniasis 62 
(Leishmania spp.) (1), human African trypanosomiasis (HAT; T. b. gambiense and T. b. 63 
rhodesiense) and the livestock disease, nagana (T. b. brucei and related African 64 
trypanosomes) (2), and Chagas’ disease (T. cruzi) (3). Collectively, these parasites cause 65 
a huge burden of disease amongst predominantly poor populations in affected regions. 66 
Leishmaniasis is caused by a range of Leishmania species, leading to cutaneous and 67 
visceral forms of the disease, of which there are 0.7-1.3 and 0.2-0.4 million cases annually 68 
(4). While cutaneous leishmaniasis can be self-limiting, infections with L. braziliensis (and 69 
other members of the Viannia sub-genus) can develop into mucocutaneous leishmaniasis, 70 
a profoundly disfiguring form of the disease (4). Visceral leishmaniasis, also known as 71 
kala-azar, is typically fatal if untreated. 72 
There are four current anti-leishmanial drugs: sodium stibogluconate (SSG), 73 
paromomycin, miltefosine and amphotericin-B, which are unsatisfactory due to toxicity, 74 
emerging drug resistance, complex administration protocols and variable efficacy 75 
depending on the disease type or infecting Leishmania species (5). With the exception of 76 
miltefosine (in use against leishmaniasis since 2002), the current anti-leishmanial drugs 77 
have been in use for many decades. Until recently, efforts have focused on the 78 
development of more effective drug delivery regimens and combination therapies, with the 79 
aim of reducing dosages (and therefore side effects) and combating the emergence of 80 
resistance. The rise of antimonial resistant L. donovani on the Indian sub-continent now 81 
precludes the use of sodium stibogluconate (SSG) (6), while miltefosine resistant L. 82 
donovani has been confirmed in the clinic (7). Consequently, the World Health 83 
Organisation recommends various combination therapies, depending on the Leishmania 84 
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species and geographical region (8). However, it is relatively easy to generate Leishmania 85 
resistant to combination therapies in the laboratory (9, 10). More recently, new drugs have 86 
entered the clinical development pipeline. However, the most advanced of these, 87 
fexinidazole, which recently passed phase 2/3 clinical trials against HAT (11), and has 88 
anti-leishmanial activity in vitro (12), lacks efficacy in vivo (13). 89 
 Given the ease with which Leishmania parasites become resistant to the available 90 
drugs, it is critically important to understand how this resistance might develop. 91 
Identification of the genetic changes underlying drug resistance will enable the 92 
development of molecular diagnostics to inform treatment choice (14). Leishmania 93 
genome and transcriptome analyses have identified large numbers of candidate genes 94 
(15, 16) but relatively few have been directly linked to drug-action. While some drugs can 95 
freely move across membranes, many are taken up via specific surface receptors and 96 
transporters. For example, miltefosine uptake is dependent on a Leishmania amino 97 
phospholipid-transporting (P4)-type ATPase (or flippase) and its β-subunit/CDC50 co-98 
factor, Ros3 (17, 18), while the Sb(III) form of SSG is taken up via an aquaglyceroporin, 99 
AQP1 (19). There is also evidence that the ABC transporter, MRPA, influences SSG 100 
uptake and sequestration (20), and several other proteins have been implicated in SSG 101 
efficacy (reviewed in (14)). In addition, the generation of drug resistant Leishmania in the 102 
laboratory and various ‘omics analyses have provided insights into anti-leishmanial drug 103 
action and resistance mechanisms. Proteomic analyses of paromomycin resistant L. 104 
donovani revealed a complex picture, with a range of proteins upregulated, including 105 
several involved in translation regulation, vesicular trafficking and glycolysis (21). A similar 106 
analysis of amphotericin-B resistant L. infantum highlighted the differential expression of 107 
metabolic enzymes and the upregulation of proteins involved in protection against reactive 108 
oxygen species (22). Metabolomic analyses suggested that oxidative defence also 109 
contributes to SSG/amphotericin-B and SSG/paromomycin resistance in L. donovani (23). 110 
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The studies described above highlight the phenotypic consequences of changes in 111 
drug sensitivity, but not necessarily the genetic changes responsible. Forward genetic 112 
approaches can identify genes that contribute to drug action and resistance. For example, 113 
genome-scale RNAi library screening, coupled with RNA interference target sequencing 114 
(RIT-seq), has revolutionised our understanding of anti-HAT drug action and resistance 115 
(24, 25). In addition, the Cos-seq approach has enabled gain-of-function screening in 116 
Leishmania (26), leading to target validation for N-myristoyltransferase (27) and the 117 
identification of a panel of putative antimony and miltefosine resistance genes (28). While 118 
undoubtedly a powerful technique, Cos-seq is unable to identify drug uptake or activation 119 
mechanisms, which can be characterised by loss-of-function approaches, such as RIT-120 
seq. However, due to the absence of the RNAi machinery in most Leishmania species 121 
(with the notable exception of L. braziliensis (29)), this loss-of-function approach is not 122 
possible in these parasites. Although T. brucei and Leishmania have distinct life cycles, 123 
they are phylogenetically related kinetoplastid parasites that exhibit a high degree of 124 
biochemical and genetic similarity (30). Indeed, the majority of orthologous genes are 125 
syntenic, indicating little change in gene-order since divergence from a common ancestor. 126 
Perhaps not surprisingly then, several ‘dual-purpose’ drugs display activity against both 127 
parasites, including pentamidine (5), fexinidazole (11, 12) and the proteasome inhibitor, 128 
GNF6702 (31). T. brucei is also susceptible to in vitro killing by the four current anti-129 
leishmanial drugs. Therefore, we hypothesised that T. brucei RNAi library selection in the 130 
anti-leishmanial drugs would enable identification of candidate drug efficacy determinants 131 
with orthologues in Leishmania. 132 
Here, we describe RIT-seq library screening using each of the current anti-133 
leishmanial drugs. We identified 44 high confidence putative drug efficacy determinants, 134 
including the T. brucei orthologues of the Leishmania SSG and miltefosine transporters. 135 
Among many previously unknown drug efficacy determinants, we found that the vesicle-136 
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associated membrane protein, TbVAMP7B, contributes to miltefosine and amphotericin-B 137 
efficacy, and highlight a role for a cohort of amino phospholipid-transporting P4-ATPases 138 
(or ‘flippases’) in driving amphotericin-B efficacy. This collection of validated and putative 139 
anti-leishmanial drug efficacy determinants provides new insight into mode-of-action and 140 
potential resistance mechanisms, and represents an important resource to guide future 141 
study.  142 
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Results 143 
Orthology-based chemogenomic profiles for anti-leishmanial drugs 144 
The four current anti-leishmanial drugs, sodium stibogluconate (SSG), 145 
paromomycin, miltefosine and amphotericin-B, have in vitro EC50 values against T. brucei 146 
of 1.8 µg.ml-1, 17 µM, 30 µM and 260 nM, respectively (Fig. 1A). The equivalent values 147 
versus intracellular L. donovani amastigotes in mouse peritoneal macrophages are 148 
approximately an order of magnitude higher (SSG, paromomycin) or lower (miltefosine, 149 
amphotericin-B) (32). To identify factors whose loss renders T. brucei less sensitive to 150 
each anti-leishmanial drug, a bloodstream-form (BSF) T. brucei RNAi library was induced 151 
for 24 hours then each drug added at 1-3X EC50; selection and induction were maintained 152 
thereafter (Fig. 1B). After selection for approximately 10 days, populations with reduced 153 
drug sensitivity emerged and grew consistently under continued selection (Fig. 1C). 154 
Following robust growth for at least two days, genomic DNA was isolated from the 155 
drug-selected populations and subjected to RNAi construct-specific PCR, generating 156 
distinct banding patterns for each (Fig. 1C). We sequenced the amplified RNAi target 157 
fragment populations from the selected RNAi libraries on an Illumina HiSeq platform 158 
(Table S1). For each selected RNAi library, we mapped more than three million individual 159 
sequence reads, representing anti-leishmanial enriched RNAi target fragments, to the 160 
TREU927 T. brucei reference genome (33) using our established RIT-seq methodology 161 
(34) (Fig. 1B). The presence of the RNAi construct-specific barcode identified ‘high 162 
confidence’ hits, i.e. those represented by more than 99 barcoded 163 
reads/kilobase/predicted transcript (open reading frames plus predicted untranslated 164 
regions, as annotated in the TREU927 reference genome available at www.tritrypdb.org), 165 
and recovery of at least two independent RNAi target fragments (Fig. 2; Fig. S1; Table 166 
S1). 167 
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Importantly, we identified T. brucei orthologues of two known Leishmania 168 
determinants of anti-leishmanial drug efficacy. RNAi target fragments that mapped to the 169 
TbAQP2-3 locus (Tb927.10.14160-70), which encodes two aquaglyceroporins, dominated 170 
the SSG-selected RNAi library; L. donovani AQP1 (LdBPK_310030.1) is a key mediator of 171 
SSG uptake (19). Another significant hit identified following miltefosine selection was a 172 
putative flippase (Tb927.11.3350); the corresponding coding sequence is syntenic with the 173 
L. donovani miltefosine transporter (LdBPK_131590.1) (17). The identification of T. brucei 174 
orthologues of these known anti-leishmanial efficacy determinants highlights the power of 175 
this chemogenomic profiling approach in the identification of mechanisms of action and 176 
resistance that are also relevant to Leishmania parasites. In addition to these hits, our RIT-177 
seq analyses yielded a further 42 high confidence hits (Fig. 2; Fig. S1; Table S1). 178 
 179 
TbAQP3, an orthologue of Leishmania AQP1, is linked to antimonial action. 180 
Aquaglyceroporin defects in T. brucei and in Leishmania have been linked to 181 
arsenical and antimonial resistance (see above), but specific relationships among drugs 182 
and AQPs have not been fully elucidated.  For example, TbAQP2 is responsible for 183 
pentamidine and melarsoprol uptake (35), possibly via receptor-mediated endocytosis in 184 
the former case (36), and mutations that disrupt TbAQP2 are responsible for melarsoprol 185 
resistance in patients (37). L. donovani AQP1 has also been linked to antimonial 186 
resistance in patients (38). Notably, TbAQP3 and Leishmania AQP1 have the same set of 187 
selectivity filter residues (NPA/NPA/WGYR), while TbAQP2 has a divergent set 188 
(NSA/NPS/IVLL) (39). Therefore, we investigated the specificity of the interaction between 189 
SSG and TbAQP2/TbAQP3, the major hits in the SSG screen. 190 
 Sequence mapping of the RNAi target fragments following SSG selection revealed 191 
that approximately 71% and 29% of mapped reads containing the RNAi construct-specific 192 
barcode corresponded to TbAQP2 (Tb927.10.14170) and TbAQP3 (Tb927.10.14160), 193 
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respectively (Fig. 3A); only 0.08% of reads mapped elsewhere in the genome. These data 194 
are consistent with the idea that both aquaglyceroporins contribute to SSG action. 195 
However, theTbAQP2 and TbAQP3 coding sequences are 82.3% identical, thus while an 196 
RNAi fragment may unambiguously map to TbAQP2, it may be sufficiently similar to 197 
TbAQP3 to elicit its depletion. Therefore, we tested the relative contribution of the encoded 198 
aquaglyceroporins to SSG action against T. brucei using aqp2-3 null and re-expression 199 
cell lines (35). 200 
Deletion of the TbAQP2-3 locus led to a 6.7-fold increase in SSG EC50 (Fig. 3B), 201 
consistent with the output from the screen. Inducible expression of GFPTbAQP2 in the null 202 
cell line had little effect on T. brucei SSG sensitivity (Fig. 3C, left-hand panel); however, 203 
GFPTbAQP3 expression reduced the SSG EC50 5.5-fold (Fig. 3C, right-hand panel). In 204 
contrast, and as shown previously (35), GFPAQP2 expression complemented the 205 
pentamidine resistance of aqp2-3 null T. brucei (Fig. 3D, left-hand panel), while GFPAQP3 206 
expression had no effect on pentamidine sensitivity (Fig. 3C, right-hand panel). Therefore, 207 
SSG sensitivity and resistance is specifically determined by TbAQP3 expression. This 208 
indicates that the NPA/NPA/WGYR selectivity filter, present in both TbAQP3 (39) and 209 
Leishmania AQP1, may be selective for antimonial uptake. 210 
 211 
T. brucei lysosomal MFST influences aminoglycoside action. 212 
Selection of the BSF T. brucei RNAi library with the anti-leishmanial 213 
aminoglycoside, paromomycin, identified 50 hits, of which 28 fulfilled our high stringency 214 
criteria (Table S1). Twenty-one of the high confidence hits were functionally annotated, 215 
and included several associated with transport and nucleic acid processing. The top three 216 
hits with functional annotations were Tb927.9.6360-80 (major facilitator superfamily 217 
transporters, MFST), Tb927.11.6680 (amino acid transporter, AAT15) and 218 
Tb927.11.14190 (Tudor domain-containing Staphylococcal nuclease, TSN) (40), targeted 219 
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by approximately 84%, 1.7% and 0.9% of the mapped reads, respectively (Fig. 4A, Fig. S2 220 
and Table S1). However, while parasites able to deplete AAT15 and TSN persisted in the 221 
population over the 12 days of selection in paromomycin, we were unable to detect a 222 
significant advantage versus wild type T. brucei during the course of a standard 72-hour 223 
EC50 assay (Fig. S1). Therefore, we focussed our attention on the MFST genes. 224 
The genes at the Tb927.9.6360-80 locus share at least 92% sequence identity and 225 
encode for three putative MFSTs, a ubiquitous family of proteins responsible for 226 
membrane transit of a wide range of solutes including drugs (41). Comparison with the 227 
sequences annotated ‘MFS’ or ‘major facilitator superfamily transporter’ in the L. major 228 
reference genome confirmed that the syntenic coding sequence, LmjF.15.0870, is most 229 
closely related to Tb927.9.6360-80 (Fig. 4B; Fig. S3). The Leishmania and T. brucei 230 
proteins share a similar trans-membrane domain organisation and the cytoplasmic loop 231 
between TM6 and TM7, which is characteristic of MFST proteins (Fig. 4C) (42). 232 
We previously identified the Tb927.9.6360-80 locus as a key contributor to suramin 233 
efficacy against T. brucei, with RNAi depletion of the three transcripts leading to a ten-fold 234 
reduction in parasite sensitivity to suramin; localisation studies also indicated that at least 235 
one of these transporters is lysosomal (24). Deletion of the whole locus (Fig. 4D) revealed 236 
that the three encoded proteins are collectively dispensable in cultured BSF T. brucei (Fig. 237 
4E), and enabled us to confirm that not only do these proteins influence suramin efficacy 238 
(Fig. 4F), but also that of paromomycin (Fig. 4G) and the related aminoglycoside, 239 
neomycin (Fig. 4H). While loss of these MFST proteins dramatically reduces suramin 240 
efficacy, the effect on paromomycin and neomycin sensitivity is less pronounced (1.5 and 241 
2.8-fold EC50 increase, respectively), though significant. Our mutant BSF T. brucei also 242 
exhibited better tolerance than wild type parasites to the aminoglycosides at 243 
concentrations equivalent to greater than EC99 during the first 24 hours of exposure (Fig. 244 
S4). 245 
.CC-BY 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/605873doi: bioRxiv preprint first posted online Apr. 11, 2019; 
 246 
TbVAMP7B, a cross-efficacy determinant for amphotericin-B and miltefosine. 247 
To identify anti-leishmanial cross-efficacy determinants, we next used pairwise 248 
comparisons of RNAi library screen outputs (Fig. 5). We first identified a small cohort of 249 
hits represented by at least two RNAi target fragments and >99 reads/kilobase/transcript in 250 
more than one screen. This group included the AQP2-3 locus, represented by at least 100 251 
reads in all four screens. We did not explore this locus further since the read-count was at 252 
least three orders of magnitude lower in each screen relative to the SSG screen, and 253 
leishmanial AQPs have not been implicated in resistance to the other drugs (see above). 254 
Two other loci fulfilled our stringency criteria, and both were enriched following 255 
amphotericin-B and miltefosine selection: Tb927.5.3550-70 and Tb927.11.3350 (Table 256 
S1); further analysis of the former hit is considered in this section, while the contribution of 257 
Tb927.11.3350 to drug action is addressed subsequently. 258 
RIT-seq analysis revealed that 2.2% and 97% of mapped reads identified 259 
Tb927.5.3550-70 in the amphotericin-B and miltefosine screens, respectively (Fig. 6A). 260 
This locus encodes for a thioredoxin-like protein (Tb927.5.3550), a vesicle-associated 261 
membrane protein, TbVAMP7B (Tb927.5.3560) (43), and a hypothetical protein 262 
(Tb927.5.3570). Analysis of the RNAi target fragments mapping to Tb927.5.3550-70 263 
revealed that few uniquely targeted the TbVAMP7B coding sequence (Fig. 6A). Instead, 264 
the RNAi target fragments that mapped to the flanking genes overlapped either the 265 
TbVAMP7B coding sequence (3550 RNAi target fragments) or 3’-untranslated region 266 
(3570 RNAi target fragments). This pattern is consistent with poor tolerance of TbVAMP7B 267 
depletion. Our previous high-throughput phenotypic analysis indicated that TbVAMP7B 268 
RNAi knockdown is associated with a significant loss of fitness, while depletion of the 269 
flanking transcripts had a less dramatic effect (Table S1) (44). Taken together, these data 270 
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suggested that TbVAMP7B is an amphotericin-B/miltefosine cross-efficacy determinant, 271 
while the identification of the flanking genes was due to bystander effects. 272 
To test this hypothesis, we generated stem-loop RNAi BSF T. brucei cell lines 273 
targeting TbVAMP7B and Tb927.5.3570. As predicted, depletion of Tb927.5.3570 had no 274 
effect on growth or sensitivity to amphotericin-B or miltefosine (Fig. S5). In contrast, 275 
knockdown of TbVAMP7B following induction in tetracycline at 2 ng or 1 μg.ml-1 resulted in 276 
a significant growth defect (Fig. 6B). To assess the contribution of TbVAMP7B to drug 277 
efficacy, we induced RNAi in 2 ng.ml-1 tetracycline for 24 hours and assessed drug 278 
sensitivity over a further 30 hours under inducing conditions. Incubation in low 279 
concentration tetracycline and a shorter EC50 analysis (as opposed to the standard 72-280 
hour protocol) ensured that the growth defect due to TbVAMP7B RNAi knockdown was 281 
minimised, while still allowing us to test the protein’s contribution to drug action.  282 
 Unexpectedly, RNAi knockdown of TbVAMP7B reduced the amphotericin-B EC50, 283 
by 24% (Fig. 6C).  However, TbVAMP7B depletion also resulted in a significant decrease 284 
in the Hill coefficient. Consequently, while the EC50 decreased upon TbVAMP7B depletion, 285 
the EC90 and EC99 increased 1.45-fold and 3-fold, respectively (Fig. 6D); the EC25 286 
decreased by 44%, consistent with the effect on the EC50 and the change in the Hill 287 
coefficient. Therefore, small changes in TbVAMP7B expression can lead to significant loss 288 
of sensitivity to high concentration amphotericin-B, while enhancing sensitivity to the drug 289 
at low concentration. This relative resistance to high concentration amphotericin-B 290 
explains the enrichment of TbVAMP7B-targeting RNAi fragments following selection of the 291 
RNAi library in 1.5x EC50. In contrast, miltefosine at relatively low concentrations 292 
complemented the TbVAMP7B RNAi growth defect and further increased growth at lower 293 
concentrations (Fig. 6E, F). 294 
Our findings indicate specific interactions between TbVAMP7B and both 295 
amphotericin-B and miltefosine. VAMP7 proteins are involved in endosome and lysosome 296 
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membrane fusion (45) and it is notable in this respect that amphotericin-B disrupts 297 
membranes and miltefosine is a phospholipid drug. TbVAMP7B depletion does not 298 
significantly increase the EC50 for either drug but, nevertheless, these interactions may be 299 
important in a clinical setting where exposure will be variable in different tissues and at 300 
different times following dosing. 301 
 302 
Multiple hits link amphotericin-B action to phospholipid transport and metabolism. 303 
Our amphotericin-B screen yielded thirteen high-confidence hits, for which Gene-304 
Ontology term profiling revealed links to membranes and lipids (Table S2; Fig. S6). This is 305 
consistent with disruption of membranes by amphotericin-B.  Miltefosine uptake in 306 
Leishmania is dependent on a flippase (17, 18), which also contributes to the anti-307 
leishmanial action of amphotericin-B (46). RNAi fragments targeting the syntenic locus in 308 
T. brucei, Tb927.11.3350, were enriched following selection in amphotericin-B and 309 
miltefosine (Fig. 5; Fig. 7A). Depletion of Tb927.11.3350, while having no effect on 310 
parasite growth in culture (Fig. 7B), led to a reproducible increase in amphotericin-B and 311 
miltefosine EC50 (Fig. 7C, D). RNAi knockdown also significantly enhanced short-term 312 
survival in high concentration amphotericin-B and miltefosine (Fig. S6). Therefore, as in 313 
Leishmania, the T. brucei miltefosine transporter orthologue contributes to the action of 314 
miltefosine and amphotericin-B. 315 
In addition to Tb927.11.3350, the T. brucei genome contains three other putative 316 
flippases (Fig. 8A), as well as three putative β-subunits, including Tb927.11.13770, the 317 
syntenic orthologue of Leishmania Ros3 (18). Three of the four flippases (Tb927.4.1510, 318 
Tb927.11.3350 and Tb927.11.13000) have a similar domain organisation to the yeast 319 
flippases and possess the DEGT and DKTGT motifs characteristic of the actuator and 320 
phosphorylation domains (47). The fourth, Tb927.6.3550, lacks the flippase DEGT domain, 321 
although it clusters with the Leishmania flippase, LmjF.34.2630. However, it also lacks the 322 
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TGES domain characteristic of the related cation transporting P-type ATPases, such as 323 
yeast Pay2 (47), so its identity is unclear (Fig. 8A). 324 
In addition to the Leishmania miltefosine transporter orthologue, Tb927.11.3350, 325 
RNAi fragments targeting the flippases, Tb927.11.13000 and Tb927.6.3550, and the β-326 
subunit, Tb927.11.13200, were enriched following selection in amphotericin-B, with 327 
Tb927.11.13000 represented by 78% of mapped reads (Fig. 8B; Table S1). Targeted RNAi 328 
depletion of Tb927.11.13000 led to a mild growth defect (Fig. 8C) and a more than two-329 
fold EC50 increase, validating this protein as an amphotericin-B efficacy determinant in T. 330 
brucei (Fig. 8D). The impact of Tb927.11.13000 depletion was most pronounced during 331 
the initial 24 hours of drug exposure, enabling the parasite population to increase 332 
approximately 1.3-fold and four-fold over eight and 24 hours, respectively, in the presence 333 
of 0.7 µM (>EC99) amphotericin-B (Fig. S6). The uninduced population declined by more 334 
than 40% and 60% over the same periods. In addition, while exposure to 1.8 µM (>EC99.9) 335 
amphotericin-B led to an 80% decline in the induced population over 24 hours, cultures of 336 
uninduced cells were cleared within four hours exposure to this drug concentration (Fig. 337 
S6). Depletion of this putative phospholipid-transporting ATPase had no effect on 338 
miltefosine efficacy (Fig. 8E) confirming its specific contribution to amphotericin-B action. 339 
 Our results reveal that multiple T. brucei flippases drive the efficacy of 340 
amphotericin-B, all of which have syntenic orthologues in Leishmania (Fig. 8A). Therefore, 341 
in addition to the well-characterised miltefosine-transporting flippase, other Leishmania 342 
flippases may play significant, and potentially specific, roles in the anti-leishmanial action 343 
of amphotericin-B and miltefosine. 344 
 345 
Discussion 346 
In the current absence of an effective genome-scale loss-of-function screen in 347 
Leishmania, we speculated that selection of a T. brucei RNAi library would provide insights 348 
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into anti-leishmanial drug action, while also revealing novel T. brucei biology. By selecting 349 
our genome-scale BSF T. brucei RNAi library in the current anti-leishmanial drugs followed 350 
by RIT-seq analysis, we identified a panel of putative anti-leishmanial drug efficacy 351 
determinants (Table S1 and Fig. S1). SSG and miltefosine selection respectively identified 352 
TbAQP3, an orthologue of the known SSG transporter, and Tb927.11.3350, the T. brucei 353 
orthologue of the Leishmania miltefosine transporter, confirming the power of this 354 
approach. In addition to these known drug transporters, we validated several novel drug 355 
efficacy determinants identified by our selective screens: Tb927.9.6360-80 (paromomycin), 356 
Tb927.5.3560 (miltefosine and amphotericin-B) and Tb927.11.13000 (amphotericin-B). 357 
Our results highlight the role of a lysosomal transporter in paromomycin efficacy, 358 
emphasise the importance of membrane composition in the action of amphotericin-B and 359 
miltefosine, provide insight into the substrate selectivity of the trypanosomatid 360 
aquaglyceroporins, and present several new candidate anti-leishmanial drug efficacy 361 
determinants (Fig. 9). 362 
T. brucei RNAi library selection in SSG and our subsequent validation experiments 363 
identified a single efficacy determinant, TbAQP3. Aquaglyceroporins are ubiquitous 364 
transporters of water, glycerol and other small solutes, whose specificity is defined by their 365 
selectivity filter residues. Leishmania AQP1 and the T. brucei proteins, TbAQP1 and 366 
TbAQP3, have the same selectivity filter, NPA/NPA/WGYR, while TbAQP2 possesses a 367 
divergent filter, NSA/NPS/IVLL (39). TbAQP2 is a key drug transporter in T. brucei, 368 
mediating the uptake of pentamidine and melarsoprol, and its loss contributes to clinical 369 
drug resistance (35-37). In addition, TbAQP2 plays an important role in glycerol transport, 370 
as its loss increases parasite sensitivity to alternative oxidase inhibition, which leads to 371 
elevated intracellular glycerol levels (48). The in vivo roles of the other T. brucei 372 
aquaglyceroporins remain unknown, though all three are capable of arsenite and 373 
antimonite transport in yeast and Xenopus heterologous expression systems (49). In 374 
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contrast, our data demonstrate that in T. brucei these transporters are selective for 375 
arsenic-containing melarsoprol (TbAQP2; (35)) and antimony-containing, SSG (TbAQP3). 376 
Intriguingly, RNAi library selection with SSG failed to identify TbAQP1 even though it 377 
contains the same selectivity filter as TbAQP3. This suggests important functional and 378 
regulatory differences between TbAQP1 and TbAQP3, which may influence their ability to 379 
contribute to SSG uptake in bloodstream-form T. brucei. For example, TbAQP3 is 380 
localised to the plasma membrane in bloodstream-form T. brucei and TbAQP1 localises to 381 
the flagella membrane (35, 50). This differential localisation may influence their ability to 382 
mediate antimonial uptake. 383 
The aminoglycoside, paromomycin, is thought to inhibit protein synthesis in 384 
Leishmania and enters the cell via endocytosis (21, 51, 52). However, RNAi library 385 
selection did not identify a surface receptor suggesting that, at least in T. brucei, 386 
paromomycin entry is not dependent on a specific ligand-receptor interaction. Rather, the 387 
high endocytic flux associated with surface VSG internalisation (53) may drive drug 388 
uptake. RNAi fragments targeting Tb927.9.6360-80 dominated the paromomycin-selected 389 
RNAi library, with the remaining 28 high confidence hits constituting only 9% of mapped 390 
reads. This locus encodes a set of closely related MFST proteins, at least one of which 391 
localises to the lysosome, and has previously been associated with suramin efficacy (24). 392 
In contrast to paromomycin, several other endocytic pathway proteins, including three 393 
lysosomal proteins (p67, cathepsin-L and the MFST proteins), influence suramin efficacy 394 
(24). This led to the proposal that proteolytic processing in the lysosome releases suramin 395 
from bound proteins, enabling neutralisation in the acidic environment or association with 396 
an alternative endogenous carrier and escape to the cytoplasm via one or more of the 397 
lysosomal MFSTs (54). In contrast, the absence of hits targeting other endocytic 398 
components following paromomycin RNAi library selection suggests little reliance on the 399 
endocytic network per se. Therefore, the lysosomal MFST proteins may influence 400 
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paromomycin efficacy indirectly. MFST proteins mediate the transit of a diverse range of 401 
molecules, including polyamines and amino acids (41), and changes in the intracellular 402 
flux of these molecules may affect translation efficiency, which in turn may influence 403 
paromomycin efficacy. Deletion of the Tb927.9.6360-80 locus from T. brucei yields only a 404 
two-fold increase in paromomycin EC50. However, the MFST protein encoded by the 405 
syntenic single copy gene in Leishmania (e.g. LmjF.15.0870) remains to be characterised 406 
and may make a more substantial contribution to paromomycin action against this 407 
parasite. 408 
Combination therapies are increasingly being used to treat leishmaniasis, enabling 409 
reduced dosing and treatment duration, resulting in fewer side effects (8). For example, a 410 
single dose of liposomal amphotericin-B in combination with a short course of oral 411 
miltefosine or intramuscular paromomycin is an effective treatment for visceral 412 
leishmaniasis (VL) in the Indian sub-continent (55). In East Africa, SSG-paromomycin 413 
combination therapy is effective against VL (56). However, L. donovani resistant to these 414 
and other anti-leishmanial drug combinations can be selected for in vitro (9, 10), and 415 
oxidative defence upregulation and changes in membrane fluidity have been associated 416 
with cross-resistance in laboratory-derived lines (23). Therefore, we carried out pairwise 417 
comparisons of our RNAi library screen data to identify potential cross-efficacy 418 
determinants. Only two hits fulfilled our stringency criteria, both of which influence 419 
amphotericin-B and miltefosine action: TbVAMP7B, an endosomal SNARE protein 420 
responsible for endosomal-lysosomal fusion in other eukaryotes (45, 57), and 421 
Tb927.11.3350, the T. brucei orthologue of the Leishmania miltefosine transporter (17). 422 
However, while both of these proteins may influence membrane fluidity (see below), it 423 
seems unlikely that either contributes significantly to oxidative defence. Recent Cos-seq 424 
gain-of-function analyses in L. infantum identified several candidate proteins whose 425 
overexpression reduces sensitivity to multi-drug exposure (26); these also lack an obvious 426 
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connection to oxidative defence. Therefore, rather than being dependent on the increase 427 
or decrease in expression of a single protein, changes in oxidative defence that lead to 428 
anti-leishmanial resistance are likely to be multi-factorial. Our findings also suggest that 429 
miltefosine/amphotericin-B combination therapy is the most vulnerable to loss-of-function 430 
mutation, while others may be less susceptible to the down-regulation of a single protein. 431 
This finding is particularly significant, given that recent trials have confirmed the efficacy of 432 
amphotericin-B/miltefosine combination therapy in treating VL (58, 59).  433 
In contrast to the other anti-leishmanial drug efficacy determinants described 434 
herein, TbVAMP7B depletion does not simply increase the drugs’ EC50. Instead, 435 
TbVAMP7B RNAi knockdown reduces amphotericin-B EC50 and has little effect on 436 
miltefosine EC50. The drop in amphotericin-B EC50 is due to a substantial decrease in the 437 
amphotericin-B Hill coefficient, which has the opposite effect on EC90 and EC99, increasing 438 
both and enabling TbVAMP7B-depleted parasites to persist at these drug concentrations. 439 
Our data shows that T. brucei has limited tolerance for TbVAMP7B depletion, presumably 440 
due to impairment of endosomal-lysosomal fusion (45). Intriguingly, exposure to low 441 
concentration miltefosine complements the growth defect seen following TbVAMP7B 442 
depletion, suggesting that miltefosine treatment is able to promote vesicle membrane 443 
fusion in the endocytic system, a possible consequence of the enhanced membrane 444 
fluidity seen upon miltefosine exposure (60). TbVAMP7B has also recently been identified 445 
as a putative T. brucei apolipoprotein-L1 sensitivity determinant (61), and other workers 446 
have highlighted the importance of the intracellular transit of apoL1-carrying membrane to 447 
trypanolysis (62, 63). Our findings suggest that such transit also contributes to 448 
amphotericin-B and miltefosine action. The VAMP7 proteins are highly conserved between 449 
T. brucei and Leishmania (43), suggesting that Leishmania parasites will also be sensitive 450 
to VAMP7B loss (LmjF.08.0030). However, subtle changes in VAMP7B expression that 451 
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can be tolerated may enable parasites to take advantage of variations in amphotericin-B 452 
and miltefosine tissue penetrance.  453 
 Miltefosine uptake in Leishmania is dependent on a phospholipid-transporting 454 
flippase (the miltefosine transporter, MT) and its β-subunit, Ros3 (17, 18); both in vitro 455 
selected lines and miltefosine resistant L. donovani clinical isolates harbour mutations in 456 
the MT (7, 64, 65). Consistent with this, T. brucei RNAi library selection in miltefosine led 457 
to enrichment for RNAi fragments mapping to the syntenic sequence in T. brucei 458 
(Tb927.11.3350). RNAi library selection in amphotericin-B also enriched for RNAi 459 
fragments mapping to this gene, consistent with recent findings in Leishmania (46), as well 460 
as two other flippases and a putative β-subunit (Tb927.11.13200). Interestingly, the β-461 
subunit targeted was not the syntenic orthologue of Ros3, previously shown to interact 462 
with the MT (18). Therefore, different flippase/β-subunit dependencies may have evolved 463 
following divergence of the Leishmania and T. brucei lineages. A further difference in the 464 
behaviour of these proteins between Leishmania and T. brucei lies in their localisation. 465 
The MT and Ros3 localise to the plasma membrane in Leishmania (18), whereas the T. 466 
brucei MT orthologue (Tb927.11.3350) and a second flippase (Tb927.11.13000) localise to 467 
an intracellular structure reminiscent of the endosomal system in procyclic form T. brucei 468 
(www.TrypTag.org; (66)). Therefore, while flippases influence drug action against 469 
Leishmania and T. brucei, they may mediate drug and/or phospholipid transit across 470 
different membranes in each parasite. 471 
Phospholipid transport by flippases maintains the membrane asymmetry necessary 472 
for membrane fusion, vesicle trafficking and sterol homeostasis (47). The identification of a 473 
single flippase following miltefosine selection is consistent with its role as a drug 474 
transporter (17). In contrast, amphotericin-B selection identified three flippases, suggesting 475 
an indirect role in drug action, possibly through changes in membrane composition and 476 
transit through the endosomal system (Fig. 9). Amphotericin-B acts by binding membrane 477 
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ergosterol (67), leading to the formation of ion-permeable channels and downstream 478 
oxidative damage (68). Consistent with the importance of ergosterol to amphotericin-B 479 
action, resistant clinical isolates exhibit elevated membrane fluidity and reduced ergosterol 480 
content (69). Recent findings have highlighted the loss of key sterol biosynthetic enzymes, 481 
and reduced ergosterol production, as a driver of resistance in laboratory-derived 482 
amphotericin-B resistant L. mexicana (70). Changes in flippase expression may similarly 483 
affect ergosterol membrane content and/or accessibility, thereby reducing sensitivity to 484 
amphotericin-B. Therefore, functional characterisation of the syntenic orthologues of these 485 
proteins in Leishmania may provide further insights into the processes and factors that 486 
drive the anti-leishmanial action of amphotericin-B.  487 
In summary, using our genome-scale BSF T. brucei RNAi library we have identified 488 
a panel of putative anti-leishmanial drug efficacy determinants, highlighting two candidate 489 
cross-efficacy determinants, as well as roles for multiple flippases in the action of 490 
amphotericin-B. The findings from this orthology-based chemogenomic profiling approach 491 
substantially advance our understanding of anti-leishmanial drug mode-of-action and 492 
potential resistance mechanisms, and should facilitate the development of improved 493 
therapies, as well as surveillance for drug-resistant parasites.  494 
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Methods 495 
T. brucei strains 496 
MITat1.2/2T1 BSF T. brucei (71) were maintained in HMI11 (Invitrogen, LifeTech) 497 
supplemented with 10% foetal calf serum (Sigma) at 37°C/5% CO2. Transfection was 498 
carried out in either cytomix or Tb-BSF buffer (72), for integration at the 2T1 ‘landing pad’ 499 
(71, 73) or Tb927.9.6360-80, respectively, using a Nucleofector (Lonza) set to programme 500 
X-001. Transformants were selected in 2.5 µg.ml-1 hygromycin, 2 µg.ml-1 puromycin or 10 501 
µg.ml-1 blasticidin, as appropriate. The BSF T. brucei RNAi library was maintained in 1 502 
µg.ml-1 phleomycin and 5 µg.ml-1 blasticidin (34). For growth assays, cultured BSF T. 503 
brucei were seeded at ~105 cells.ml-1, counted using a haemocytometer, and diluted back 504 
every 24 hours, as necessary, for three days in the absence of antibiotics. All selective 505 
antibiotics were purchased from Invivogen. 506 
 507 
Drug sensitivity assays 508 
Half-maximal effective concentrations (EC50) of the anti-leishmanial drugs (sodium 509 
stibogluconate, GSK; paromomycin, Sigma; miltefosine, Paladin; amphotericin-B, E R 510 
Squibb, UK) and neomycin (G418, Invivogen) were determined over 78 or 30 hours. BSF 511 
T. brucei were seeded at 2x103 (or 2x105) cells.ml-1 in 96-well plates in a 2-fold dilution 512 
series of each drug; assays were carried out in the absence of other antibiotics. After 72 or 513 
24 hours, resazurin (Sigma) in PBS was added to a final concentration of 12.5 µg.ml-1 per 514 
well, and the plates incubated for a further 6 hours at 37°C. Fluorescence was determined 515 
using a fluorescence plate reader (Molecular Devices) at an excitation wavelength of 530 516 
nm, an emission wavelength of 585 nm and a filter cut-off of 570 nm (74). Data were 517 
processed in Microsoft Excel, and non-linear regression analysis carried out in GraphPad 518 
Prism. The short-term kinetics of killing in high concentration drug (>EC99) were 519 
determined in triplicate over 24 hours from a starting cell density of 1x105 cells.ml-1. 520 
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 521 
T. brucei RNAi library screening and RIT-seq 522 
RNA library screening was carried out as previously described (34). Briefly, library 523 
expression was induced in 1 µg.ml-1 tetracycline (Sigma) for 24 hours prior to selection in 524 
each anti-leishmanial drug at 1-3X EC50. Cell density was assessed daily using a 525 
haemocytometer and diluted to no less than 20 million cells in 100 ml media; induction and 526 
anti-leishmanial drug selection were maintained throughout. Once robust growth had been 527 
achieved for at least two days, genomic DNA was prepared for RNAi target identification. 528 
The RNAi cassettes remaining in the anti-leishmanial-selected RNAi libraries were 529 
amplified from genomic DNA using the LIB2F/LIB2R primers and sequenced on an 530 
Illumina HiSeq platform at the Beijing Genome Institute. 531 
The sequenced RNAi target fragments were mapped against the T. brucei strain 532 
TREU927 reference genome (release 6.0), as described (34). Briefly, mapping was carried 533 
out using Bowtie2 (75) set to ‘very sensitive local’ alignment and output SAM files were 534 
processed using SAMtools (76). The resultant BAM files were viewed against the 535 
reference genome in the Artemis genome browser (77). Reads containing the RNAi 536 
construct-specific 14-base barcode were identified using a custom script (34), and 537 
corresponded to at least 22% of reads from each selected RNAi library. This subset of 538 
reads were mapped against the TREU927 reference genome, as above. Plots were 539 
generated using the Artemis graph tool and processed in Adobe Photoshop Elements 8.0. 540 
Stacks of reads that included the 14-base barcode on the positive strand were used to 541 
define RNAi target fragment junctions and to assign high-confidence hits as those 542 
identified by at least two RNAi target fragments.  RNAi target fragment read numbers were 543 
converted to RPKM (reads/kilobase/million reads mapped) to account for inter-library read-544 
depth variations when comparing RNAi library sequencing outputs. 545 
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Alignments were carried out in Clustal Omega 546 
(https://www.ebi.ac.uk/Tools/msa/clustalo/), unrooted neighbour joining trees were 547 
formatted in Dendroscope 3 (http://dendroscope.org/) (78) and putative trans-membrane 548 
domains identified using TOPCONS (http://topcons.cbr.su.se/) (79). GO-term profiles were 549 
constructed using the GO analysis tool at http://tritrypdb.org. 550 
 551 
Plasmid and T. brucei strain construction and analysis 552 
Tb927.9.6360-80 locus targeting fragments were cloned into pPAC and pBSD, 553 
enabling replacement of both alleles of the three-gene locus with puromycin 554 
acetyltransferase (PAC) and blasticidin-S deaminase (BSD) open reading frames. Stem-555 
loop RNAi constructs targeting Tb927. 11.6680 (AAT15), Tb927.11.13000, Tb927.11.3350, 556 
Tb927.5.3560 (TbVAMP7B) and Tb927.5.3570 were assembled in pRPa-iSL (73). RNAi 557 
targeting fragments were designed using the RNAit primer design algorithm to minimise 558 
off-target effects (80). pRPa-iSL constructs were linearised with AscI (NEB) prior to 559 
transfection and targeted integration at the rDNA spacer ‘landing pad’ locus in 2T1 BSF T. 560 
brucei (71). Details of all primers are available upon request. Tb927.9.6360-80 allelic 561 
replacement was confirmed by Southern hybridisation following XhoI (New England 562 
Biolabs) digestion of genomic DNA. RNAi knockdown was confirmed by northern 563 
hybridisation of total RNA or, in the case of Tb927.11.6680, by RT-qPCR, as described 564 
(81). For Southern and northern hybridisation, digoxigenin-dUTP (Roche) labelled DNA 565 
probes were generated by PCR, hybridised and detected according to standard protocols 566 
and the manufacturer’s instructions. 567 
 568 
Data availability 569 
Sequence data are available as fastq files at the European Nucleotide Archive 570 
(https://www.ebi.ac.uk/ena) under study accession number, PRJEB31973 (amphotericin-B, 571 
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ERS3348616; miltefosine, ERS3348617; paromomycin, ERS3348618; sodium 572 
stibogluconate, ERS3348619).  573 
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Figure legends 838 
 839 
Figure 1 840 
Anti-leishmanial drug selection of a genome-scale T. brucei RNAi library. A) 841 
Representative EC50 charts showing the susceptibility of T. brucei to the anti-leishmanial 842 
drugs. Individual EC50 assays were carried out in quadruplicate; error bars represent 843 
standard deviation. Insets: structures of the anti-leishmanial drugs 844 
(www.Chemspider.com). B) Schematic showing bloodstream-form T. brucei RNAi library 845 
selection and RNAi fragment identification by RIT-seq. C) Growth during anti-leishmanial 846 
drug selection of the BSF T. brucei RNAi library; selection was initiated in 1.5X EC50, 847 
except for miltefosine (1.0X EC50), and adjusted as indicated (black arrows); induction in 1 848 
µg.ml-1 tetracycline was maintained throughout. Genomic DNA prepared at the indicated 849 
times (red arrows). Insets: RNAi library-specific PCR.  850 
 851 
Figure 2 852 
Genome-scale maps showing hits in each screen. Illumina sequencing of the amplified 853 
RNAi target fragments identifies T. brucei orthologues of known Leishmania drug 854 
transporters and novel putative drug efficacy determinants. RNAi fragments amplified from 855 
each selective screen were mapped against the TREU927 T. brucei reference genome. 856 
Red bars correspond to T. brucei orthologues of known Leishmania drug transporters: 857 
AQP2-3, aquaglyceroporin-2-3 locus, Tb927.10.14160-70; MT, miltefosine transporter 858 
orthologue, Tb927.11.3350. The y-axes are truncated to 104 reads/kilobase/transcript. 859 
SSG, sodium stibogluconate; Pmm, paromomycin; Milt, miltefosine; AmB, amphotericin-B.  860 
 861 
Figure 3 862 
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TbAQP3, a T. brucei orthologue of Leishmania AQP1, is selective for sodium 863 
stibogluconate. A) Total (red) and RNAi construct-specific 14mer-containing (blue) reads 864 
mapping to the TbAQP2-3 locus, Tb927.10.14160-70. Targeted open reading frames 865 
highlighted in green; flanking open reading frames coloured grey. B) Sodium 866 
stibogluconate EC50 assay following deletion of the T. brucei AQP2-3 locus (aqp2-3). C) 867 
Sodium stibogluconate and D) pentamidine EC50 assays following expression of GFPAQP2 868 
(left panels) and GFPAQP3 (right panels) in aqp2-3 null T. brucei. Individual EC50 assays 869 
were carried out in quadruplicate. Error bars represent standard deviation. WT, T. brucei 870 
wild type for the AQP2-3 locus. 871 
 872 
Figure 4 873 
The T. brucei lysosomal major facilitator superfamily protein influences the efficacy 874 
of aminoglycoside drugs. A) Total (red) and RNAi construct-specific 14mer-containing 875 
(blue) reads mapping to the MFST locus, Tb927.9.6360-80. Targeted open reading frames 876 
highlighted in green; flanking open reading frames coloured grey. B) Unrooted neighbour 877 
joining tree comparing representative Leishmania MFST proteins with Tb927.9.6360-80 878 
(highlighted in green; see Fig. S3 for extended tree). C) Predicted trans-membrane 879 
organisation of the Tb927.9.6360-80 proteins and the selected Leishmania proteins (TM 880 
domains, vertical bars). D) MFST locus deletion strategy and Southern hybridisation 881 
confirming generation of heterozygous (-/+) and homozygous (-/-) MFST locus null T. 882 
brucei. X, XhoI; D, deletion probe; F, flanking probe; PAC, puromycin acetyltransferase; 883 
BSD, blasticidin S-deaminase; WT, wild type. E) Growth of WT and MFST locus null (mfst) 884 
T. brucei in culture. F-H) Representative EC50 assays comparing the sensitivity of WT and 885 
mfst T. brucei to F) suramin, G) paromomycin and H) neomycin. Inset charts summarise 886 
EC50 data from three independent biological replicates. Individual growth (E) and EC50 (F-887 
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H) assays were carried out in triplicate and quadruplicate, respectively. Error bars 888 
represent standard deviation. P-values derived from Student’s t-test (** P<0.01). 889 
 890 
Figure 5 891 
Pairwise comparisons identify putative amphotericin-B/miltefosine cross-efficacy 892 
loci. Pairwise comparisons of the sequenced outputs from the four selective screens. Data 893 
converted to reads per kilobase per million mapped reads (RPKM) to control for minor 894 
inter-library variations in read depth. Dashed lines represent stringent 100-read cut offs for 895 
each selected RNAi library converted to RPKM. High confidence cross-efficacy 896 
determinants highlighted in red in the top right quadrant following comparison of the 897 
miltefosine and amphotericin-B selected RNAi libraries. 898 
 899 
Figure 6 900 
T. brucei VAMP7B, Tb927.5.3560, and the action of amphotericin-B and miltefosine. 901 
A) Total (red) and RNAi construct-specific 14mer-containing (blue) reads mapping to 902 
Tb927.5.3550-70 following amphotericin-B and miltefosine selection. Targeted open 903 
reading frames highlighted in green; flanking open reading frames coloured grey. B) T. 904 
brucei population growth following TbVAMP7B (Tb927.5.3560) RNAi knockdown. Inset: 905 
confirmation of RNAi knockdown by northern blot following 24-hour induction in 1 µg.ml-1 906 
tetracycline; ethidium bromide stained gel shown as a loading control. C) Representative 907 
30-hour amphotericin-B EC50 assay following TbVAMP7B RNAi knockdown induced in 2 908 
ng.ml-1 tetracycline. Inset chart summarises Hill coefficient data for five biological 909 
replicates. D) The effect of TbVAMP7B RNAi knockdown on ECX for five biological 910 
replicates; data derived for each replicate from EC50 values and Hill coefficients presented 911 
in (C). E) Representative 30-hour miltefosine EC50 assay following TbVAMP7B RNAi 912 
knockdown induced in 2 ng.ml-1 tetracycline; data plotted to show population growth 913 
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relative to untreated T. brucei (uninduced or induced). Dashed ellipse highlights 914 
miltefosine-mediated complementation of the Tb927.5.3560 RNAi growth defect. F) Chart 915 
summarising T. brucei population growth in the presence or absence of TbVAMP7B RNAi 916 
in a subset of miltefosine concentrations from five independent biological replicates. 917 
Individual growth (B) and EC50 (C, E) assays were carried out in triplicate and 918 
quadruplicate, respectively. Error bars represent standard deviation. P-values derived from 919 
paired Student’s t-test (** <0.01; *** <0.001).  920 
 921 
Figure 7 922 
The T. brucei miltefosine transporter orthologue, Tb927.11.3350, influences 923 
miltefosine and amphotericin-B efficacy against T. brucei. A) Total (red) and RNAi 924 
construct-specific 14mer-containing (blue) reads mapping to Tb927.11.3350 following 925 
amphotericin-B (AmB) or miltefosine selection. Targeted open reading frames highlighted 926 
in green; flanking open reading frames coloured grey. B) T. brucei population growth 927 
following RNAi knockdown of Tb927.11.3350. Inset: confirmation of RNAi knockdown by 928 
northern blot; ethidium bromide stained gel shown as a loading control. C, D) 929 
Representative amphotericin-B and miltefosine EC50 assays following RNAi knockdown of 930 
Tb927.11.3350. Inset charts summarise data from three independent biological replicates. 931 
Individual growth (B) and EC50 (C, D) assays were carried out in triplicate and 932 
quadruplicate, respectively. Error bars represent standard deviation. P-values derived from 933 
Student’s t-test (* <0.05; ** <0.01). RNAi inductions were carried out in 1 µg.ml-1 934 
tetracycline. 935 
 936 
Figure 8 937 
Flippases influence the action of amphotericin-B. A) Neighbour joining phylogenetic 938 
tree showing the T. brucei and L. major flippases versus the S. cerevisiae flippases 939 
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(Neo1p, Drs2p and DNF1-3) and a representative cation-transporting P-type ATPase 940 
(Pay2). Schematics of predicted T. brucei and L. major flippases and representative S. 941 
cerevisiae flippases (Neo1p and DNF3) and P-type ATPase (Pay2), highlighting key 942 
conserved residues (actuator domain: TGES [green triangle], DEGT [pink triangle]; and, 943 
phosphorylation domain, DKTGT [yellow triangle]); predicted signal peptide, vertical red 944 
bar; and, predicted trans-membrane domain organisation, vertical black bars. B) Total 945 
(red) and RNAi construct-specific 14mer-containing (blue) reads mapping to 946 
Tb927.11.13000 and Tb927.6.3550 following amphotericin-B selection. Targeted open 947 
reading frames highlighted in green; flanking open reading frames coloured grey. C) T. 948 
brucei population growth following RNAi knockdown of Tb927.11.13000. Inset: 949 
confirmation of RNAi knockdown by northern blot; ethidium bromide stained gel shown as 950 
a loading control.  D, E) Representative amphotericin-B and miltefosine EC50 assays 951 
following RNAi knockdown of Tb927.11.13000. Inset charts summarise data from three 952 
independent biological replicates. Individual growth (C) and EC50 (D, E) assays were 953 
carried out in triplicate and quadruplicate, respectively. Error bars represent standard 954 
deviation. P-values derived from Student’s t-test (* <0.05; ** <0.01). RNAi inductions were 955 
carried out in 1 µg.ml-1 tetracycline, unless otherwise stated. 956 
 957 
Figure 9 958 
Known and candidate drivers of anti-leishmanial drug efficacy in Leishmania. The 959 
key T. brucei proteins identified in our anti-leishmanial loss-of-function screen (left hand 960 
panel) and their Leishmania orthologues (right hand panel) represent candidate anti-961 
leishmanial drug efficacy determinants. Red denotes known Leishmania drivers of anti-962 
leishmanial efficacy whose loss-of-function reduces drug efficacy (see text for details). The 963 
strain prefix for the truncated gene IDs is at the top of each panel, with the exception of the 964 
sterol biosynthetic enzymes recently shown to contribute to amphotericin-B efficacy 965 
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against L. mexicana (70). Grey-filled circles (endosomes) and ellipses (lysosome) 966 
represent the endocytic system. The purple block represents membrane modified by 967 
changes in sterol biosynthesis and the putative action of the flippases and their β-subunit; 968 
changes in membrane composition anywhere in the endocytic system may influence the 969 
intracellular transit of amphotericin-B or its ability to form ion permeable channels.  970 
 971 
Figure S1 972 
Candidate anti-leishmanial drug efficacy determinants identified by T. brucei RNAi 973 
library selection.  Total (red) and RNAi construct-specific 14mer-containing (blue) reads 974 
mapping to individual loci following BSF T. brucei RNA library selection in paromomycin 975 
(A), amphotericin-B (B) and miltefosine (C). Targeted open reading frames highlighted in 976 
green; flanking open reading frames coloured grey. Where a substantial number of reads 977 
target regions outside the open reading frame, the predicted untranslated region is 978 
highlighted by a narrow green bar. See Table S1 for further details. 979 
 980 
Figure S2 981 
Neither AAT15 (Tb927.11.6680) depletion nor Tudor Staphylococcal nuclease 982 
(Tb927.11.14190) deletion affects aminoglycoside efficacy against BSF T. brucei 983 
over 72 hours. A, B) Total (red) and RNAi construct-specific 14mer-containing (blue) 984 
reads mapping to Tb927.11.6680 (A) and Tb927.11.14190 (B) following paromomycin 985 
selection. Targeted open reading frames highlighted in green; flanking open reading 986 
frames coloured grey. C) T. brucei population growth following AAT15 RNAi knockdown. 987 
Inset: RNA depletion was confirmed by RT-qPCR following 24-hour induction in 1 µg.ml-1 988 
tetracycline. D, E) Representative paromomycin and neomycin EC50 assays following 989 
AAT15 RNAi knockdown induced in 1 µg.ml-1 tetracycline. F, G) Representative 990 
paromomycin (D) and neomycin (E) EC50 assays comparing wild type and 991 
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Tb927.11.14190 null (tsn) BSF T. brucei. Inset charts summarise data from three 992 
independent biological replicates. Individual growth (C) and EC50 (D-G) assays were 993 
carried out in triplicate and quadruplicate, respectively. Error bars represent standard 994 
deviation. 995 
 996 
Figure S3 997 
Tb927.9.6360-80 clusters with the syntenic LmjF.15.0870. Twenty nine open reading 998 
frames annotated ‘major facilitator’ or ‘MFS’ in the L. major Friedlin reference genome 999 
were aligned with the Tb927.9.6360-80 open reading frames using Clustal Omega 1000 
(https://www.ebi.ac.uk/Tools/msa/clustalo/). The unrooted neighbour joining phylogenetic 1001 
tree was formatted in Dendroscope 3 (http://dendroscope.org/). 1002 
 1003 
Figure S4 1004 
MFST locus null T. brucei exhibit enhanced tolerance to high concentration 1005 
aminoglycosides. Relative population growth of wild type (WT) and MFST locus null 1006 
(mfst) T. brucei in A) paromomycin and B) neomycin at >EC99. Assays were carried out in 1007 
triplicate. Error bars represent standard deviation. 1008 
 1009 
Figure S5 1010 
Tb927.5.3570 does not contribute to the efficacy of amphotericin-B or miltefosine 1011 
against T. brucei. A) T. brucei population growth following Tb927.5.3570 RNAi 1012 
knockdown. Inset: confirmation of RNAi knockdown by northern blot; ethidium bromide 1013 
stained gel shown as a loading control. B, C) Representative amphotericin-B and 1014 
miltefosine EC50 assays following Tb927.5.3570 RNAi knockdown. RNAi inductions were 1015 
carried out in 1 µg.ml-1 tetracycline. Individual growth (A) and EC50 (B, C) assays were 1016 
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carried out in triplicate and quadruplicate, respectively. Error bars represent standard 1017 
deviation. 1018 
 1019 
Figure S6 1020 
Gene Ontology analysis of the high confidence hits identified following 1021 
amphotericin-B RNAi library selection. Plot generated using the GO analysis tool at 1022 
TritrypDB.org. Point diameter corresponds to relative number of proteins in each category. 1023 
See Table S2 for further details. 1024 
 1025 
Figure S7 1026 
T. brucei exhibit enhanced tolerance to high concentration amphotericin-B following 1027 
flippase depletion. A, C) Representative assays showing relative population growth in 1028 
>EC99 amphotericin-B following (A) Tb927.11.3350 and (C) Tb927.11.13000 RNAi 1029 
knockdown. B, D) Relative population growth in >EC99 amphotericin-B following (B) 1030 
Tb927.11.3350 and (D) Tb927.11.13000 RNAi knockdown; data derived from three 1031 
independent biological replicates. Individual growth assays were carried out in triplicate. 1032 
Error bars represent standard deviation. P-values derived from Student’s t-test (* <0.05; 1033 
*** <0.001). RNAi inductions were carried out in 1 µg.ml-1 tetracycline. 1034 
 1035 
Table S1 1036 
Transcripts represented by >99 RNAi construct-specific barcode-containing reads per 1037 
kilobase per transcript following BSF T. brucei RNAi library selection in the anti-leishmanial 1038 
drugs. 1039 
 1040 
Table S2 1041 
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Gene Ontology analysis of the high confidence hits identified by amphotericin-B RNAi 1042 
library selection. 1043 
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Figure 1
Anti-leishmanial drug selection of a genome-scale T. brucei RNAi library. A) Representative 
EC50 charts showing the susceptibility of T. brucei to the anti-leishmanial drugs. Individual EC50
assays were carried out in quadruplicate; error bars represent standard deviation. Insets: 
structures of the anti-leishmanial drugs (www.Chemspider.com). B) Schematic showing 
bloodstream-form T. brucei RNAi library selection and RNAi fragment identification by RIT-seq. C) 
Growth during anti-leishmanial drug selection of the BSF T. brucei RNAi library; selection was 
initiated in 1.5X EC50, except for miltefosine (1.0X EC50), and adjusted as indicated (black arrows); 
induction in 1 µg.ml-1 tetracycline was maintained throughout. Genomic DNA prepared at the 
indicated times (red arrows). Insets: RNAi library-specific PCR. 
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Figure 2
Genome-scale maps showing hits in each screen. Illumina sequencing of the amplified RNAi 
target fragments identifies T. brucei orthologues of known Leishmania drug transporters and novel 
putative drug efficacy determinants. RNAi fragments amplified from each selective screen were 
mapped against the TREU927 T. brucei reference genome. Red bars correspond to T. brucei
orthologues of known Leishmania drug transporters: AQP2-3, aquaglyceroporin-2-3 locus, 
Tb927.10.14160-70; MT, miltefosine transporter orthologue, Tb927.11.3350. The y-axes are 
truncated to 104 reads/kilobase/transcript. SSG, sodium stibogluconate; Pmm, paromomycin; Milt, 
miltefosine; AmB, amphotericin-B.
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TbAQP3, a T. brucei orthologue of Leishmania AQP1, is selective for sodium 
stibogluconate. A) Total (red) and RNAi construct-specific 14mer-containing (blue) reads mapping 
to the TbAQP2-3 locus, Tb927.10.14160-70. Targeted open reading frames highlighted in green; 
flanking open reading frames coloured grey. B) Sodium stibogluconate EC50 assay following 
deletion of the T. brucei AQP2-3 locus (aqp2-3). C) Sodium stibogluconate and D) pentamidine
EC50 assays following expression of 
GFPAQP2 (left panels) and GFPAQP3 (right panels) in aqp2-3 
null T. brucei. Individual EC50 assays were carried out in quadruplicate. Error bars represent 
standard deviation. WT, T. brucei wild type for the AQP2-3 locus.
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The T. brucei lysosomal major facilitator superfamily protein influences the efficacy of 
aminoglycoside drugs. A) Total (red) and RNAi construct-specific 14mer-containing (blue) reads mapping 
to the MFST locus, Tb927.9.6360-80. Targeted open reading frames highlighted in green; flanking open 
reading frames coloured grey. B) Unrooted neighbour joining tree comparing representative Leishmania
MFST proteins with Tb927.9.6360-80 (highlighted in green; see Fig. S3 for extended tree). C) Predicted 
trans-membrane organisation of the Tb927.9.6360-80 proteins and the selected Leishmania proteins (TM 
domains, vertical bars). D) MFST locus deletion strategy and Southern hybridisation confirming generation 
of heterozygous (-/+) and homozygous (-/-) MFST locus null T. brucei. X, XhoI; D, deletion probe; F, flanking 
probe; PAC, puromycin acetyltransferase; BSD, blasticidin S-deaminase; WT, wild type. E) Growth of WT 
and MFST locus null (mfst) T. brucei in culture. F-H) Representative EC50 assays comparing the sensitivity 
of WT and mfst T. brucei to F) suramin, G) paromomycin and H) neomycin. Inset charts summarise EC50
data from three independent biological replicates. Individual growth (E) and EC50 (F-H) assays were carried 
out in triplicate and quadruplicate, respectively. Error bars represent standard deviation. P-values derived 
from Student’s t-test (** P<0.01).
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Pairwise comparisons identify putative amphotericin-B miltefosine cross-efficacy loci.
Pairwise comparisons of the sequenced outputs from the four selective screens. Data converted to 
reads per kilobase per million mapped reads (RPKM) to control for minor inter-library variations in 
read depth. Dashed lines represent stringent 100-read cut offs for each selected RNAi library 
converted to RPKM. High confidence cross-efficacy determinants highlighted in red in the top right 
quadrant following comparison of the miltefosine and amphotericin-B selected RNAi libraries.
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T. brucei VAMP7B, Tb927.5.3560, and the action of amphotericin-B and miltefosine. A) Total (red) and 
RNAi construct-specific 14mer-containing (blue) reads mapping to Tb927.5.3550-70 following amphotericin-
B and miltefosine selection. Targeted open reading frames highlighted in green; flanking open reading 
frames coloured grey. B) T. brucei population growth following TbVAMP7B (Tb927.5.3560) RNAi 
knockdown. Inset: confirmation of RNAi knockdown by northern blot following 24-hour induction in 1 µg.ml-1
tetracycline; ethidium bromide stained gel shown as a loading control. C) Representative 30-hour 
amphotericin-B EC50 assay following TbVAMP7B RNAi knockdown induced in 2 ng.ml
-1 tetracycline. Inset 
chart summarises Hill coefficient data for five biological replicates. D) The effect of TbVAMP7B RNAi 
knockdown on ECX for five biological replicates; data derived for each replicate from EC50 values and Hill 
coefficients presented in (C). E) Representative 30-hour miltefosine EC50 assay following TbVAMP7B RNAi 
knockdown induced in 2 ng.ml-1 tetracycline; data plotted to show population growth relative to untreated T. 
brucei (uninduced or induced). Dashed ellipse highlights miltefosine-mediated complementation of the 
Tb927.5.3560 RNAi growth defect. F) Chart summarising T. brucei population growth in the presence or 
absence of TbVAMP7B RNAi in a subset of miltefosine concentrations from five independent biological 
replicates. Individual growth (B) and EC50 (C, E) assays were carried out in triplicate and quadruplicate, 
respectively. Error bars represent standard deviation. P-values derived from paired Student’s t-test (** 
<0.01; *** <0.001). 
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The T. brucei miltefosine transporter orthologue, Tb927.11.3350, influences miltefosine and 
amphotericin-B efficacy against T. brucei. A) Total (red) and RNAi construct-specific 14mer-
containing (blue) reads mapping to Tb927.11.3350 following amphotericin-B (AmB) or miltefosine
selection. Targeted open reading frames highlighted in green; flanking open reading frames 
coloured grey. B) T. brucei population growth following RNAi knockdown of Tb927.11.3350. Inset: 
confirmation of RNAi knockdown by northern blot; ethidium bromide stained gel shown as a loading 
control. C, D) Representative amphotericin-B and miltefosine EC50 assays following RNAi 
knockdown of Tb927.11.3350. Inset charts summarise data from three independent biological 
replicates. Individual growth (B) and EC50 (C, D) assays were carried out in triplicate and 
quadruplicate, respectively. Error bars represent standard deviation. P-values derived from 
Student’s t-test (* <0.05; ** <0.01). RNAi inductions were carried out in 1 µg.ml-1 tetracycline.
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Flippases influence the action of amphotericin-B. A) Neighbour joining phylogenetic tree 
showing the T. brucei and L. major flippases versus the S. cerevisiae flippases (Neo1p, Drs2p and 
DNF1-3) and a representative cation-transporting P-type ATPase (Pay2). Schematics of predicted 
T. brucei and L. major flippases and representative S. cerevisiae flippases (Neo1p and DNF3) and 
P-type ATPase (Pay2), highlighting key conserved residues (actuator domain: TGES [green 
triangle], DEGT [pink triangle]; and, phosphorylation domain, DKTGT [yellow triangle]); predicted 
signal peptide, vertical red bar; and, predicted trans-membrane domain organisation, vertical black 
bars. B) Total (red) and RNAi construct-specific 14mer-containing (blue) reads mapping to 
Tb927.11.13000 and Tb927.6.3550 following amphotericin-B selection. Targeted open reading 
frames highlighted in green; flanking open reading frames coloured grey. C) T. brucei population 
growth following RNAi knockdown of Tb927.11.13000. Inset: confirmation of RNAi knockdown by 
northern blot; ethidium bromide stained gel shown as a loading control.  D, E) Representative 
amphotericin-B and miltefosine EC50 assays following RNAi knockdown of Tb927.11.13000. Inset 
charts summarise data from three independent biological replicates. Individual growth (C) and EC50
(D, E) assays were carried out in triplicate and quadruplicate, respectively. Error bars represent 
standard deviation. P-values derived from Student’s t-test (* <0.05; ** <0.01). RNAi inductions were 
carried out in 1 µg.ml-1 tetracycline, unless otherwise stated.
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Figure 9
AQP3 (10.14160)
LysoMFST (9.6360-80)
Flippases: MT (11.3350), 
11.13000, 6.3550
β-subunit: 11.13200
MT (11.3350)
Translation
?
SSG
Paromomycin
Amphotericin-B
Miltefosine
AQP1 (31.0020)
(15.0870)
MT (13.1530)
β-subunit, Ros3 (32.0510)
Translation
?
Flippases: MT (13.1530), 
09.0890, 30.2260
β-subunit: 09.1020
T. brucei (Tb927) Leishmania (LmjF)
Membrane 
organisation
VAMP7B (5.3560) (08.0030)
Membrane 
organisation
Sterol synthesis: 
SMT (LmxM.36.2380), 
SC5D (LmxM.23.1300)
Known and candidate drivers of anti-leishmanial drug efficacy in Leishmania. The key T. 
brucei proteins identified in our anti-leishmanial loss-of-function screen (left hand panel) and their 
Leishmania orthologues (right hand panel) represent candidate anti-leishmanial drug efficacy 
determinants. Red denotes known Leishmania drivers of anti-leishmanial efficacy whose loss-of-
function reduces drug efficacy (see text for details). The strain prefix for the truncated gene IDs is 
at the top of each panel, with the exception of the sterol biosynthetic enzymes recently shown to 
contribute to amphotericin-B efficacy against L. mexicana [66]. Grey-filled circles (endosomes) and 
ellipses (lysosome) represent the endocytic system. The purple block represents membrane 
modified by changes in sterol biosynthesis and the putative action of the flippases and their β-
subunit; changes in membrane composition anywhere in the endocytic system may influence the 
intracellular transit of amphotericin-B or its ability to form ion permeable channels. 
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